AN2 Therapeutics, Inc. (ANTX) Operating cash flow 2021–2025
AN2 Therapeutics, Inc. (ANTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$29.8MFY2025 · since FY2021: -$20.5M → -$29.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$29.8M | +39.4% |
| FY2024 | -$49.3M | +7.6% |
| FY2023 | -$53.3M | -59.2% |
| FY2022 | -$33.5M | -63.4% |
| FY2021 | -$20.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ANTX financial trends
ANTX RevenueANTX Net incomeANTX Net marginANTX Gross profitANTX Gross marginANTX Operating incomeANTX Operating marginANTX Free cash flowANTX Capital expendituresANTX Return on equityANTX Stock buybacksANTX Dividends paidANTX Total assetsANTX Total liabilitiesANTX Shareholders’ equityANTX overview →